StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Development by Quarter

Development — Outsourced clinical trials, CROs, manufacturing & other direct costs ($M) ($M)

QuarterlyAnnual

Vertex Pharmaceuticals Development: $368M in Q2 2026, down 1.3% from a year earlier.

Latest, Q2 2026
368
Period ended Jun 30, 2026
Change on a year earlier
-1.3%
373 in Q2 2025
History
34 quarters
Since Q1 2018
Sources
28
Documents cited below

Where the Q2 2026 figure comes from

“|| Outsourced services and other direct expenses | 367.7 | 372.5 | (1)% | 693.9 | 752.2 | (8)%”

Source: Form 10-Q (vrtx-20260630.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K MD&A (Development Expenses Disaggregation Table).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDevelopment — Outsourced clinical trials, CROs, manufacturing & other direct costs ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026368-1.3%Form 10-Q (vrtx-20260630.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026326-14.1%Form 10-Q (vrtx-20260331.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 2025377-9.6%Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
Q3 2025Sep 30, 2025365+14.2%Form 10-Q (vrtx-20250930.htm, filed 2025-11-04) ↗
Q2 2025Jun 30, 2025373+39.4%Form 10-Q (vrtx-20260630.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 2025380+60.8%Form 10-Q (vrtx-20260331.htm, filed 2026-05-05) ↗
Q4 2024Dec 31, 2024416+47.8%Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
Q3 2024Sep 30, 2024319-4.0%Form 10-Q (vrtx-20250930.htm, filed 2025-11-04) ↗
Q2 2024Jun 30, 2024267-18.8%Form 10-Q (vrtx-20250630.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 2024236-20.0%Form 10-Q (vrtx-20250331.htm, filed 2025-05-06) ↗
Q4 2023Dec 31, 2023282+2.9%Form 10-K (vrtx-20251231.htm, filed 2026-02-13) ↗
Q3 2023Sep 30, 2023333+54.1%Form 10-Q (vrtx-20240930.htm, filed 2024-11-05) ↗
Q2 2023Jun 30, 2023329+56.3%Form 10-Q (vrtx-20240630.htm, filed 2024-08-02) ↗
Q1 2023Mar 31, 2023295+38.8%Form 10-Q (vrtx-20240331.htm, filed 2024-05-07) ↗
Q4 2022Dec 31, 2022274+34.8%Form 10-K (vrtx-20241231.htm, filed 2025-02-13) ↗
Q3 2022Sep 30, 2022216+44.3%Form 10-Q (vrtx-20230930.htm, filed 2023-11-07) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Development ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/rd-dev-outsourced

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.